Redeyes sees CellaVision’s Q2 report this morning as very much in line with our expectations. The corona crisis had the expected impact on the company during the second quarter. The company continue to guide for a negative impact on sales and earnings over the coming months. We maintain our optimistic view and leave our fair value range unchanged.